Introduction
============

The incidence and mortality of diabetes have been increasing rapidly in recent decades worldwide ([@b1-mmr-17-01-1775]). The mortality of diabetes is predominantly due to its severe cardiovascular complications ([@b2-mmr-17-01-1775]). Diabetic cardiomyopathy (DbCM) is one of the major clinical manifestations of diabetic cardiovascular complications, which is characterized by cardiac dysfunction and arrhythmia ([@b3-mmr-17-01-1775]). As one of the most noteworthy pathological features of DbCM, cardiac fibrosis leads to cardiac remodeling, cardiac dilatation and congestive heart failure ([@b4-mmr-17-01-1775]).

The essential pathological characteristic of cardiac fibrosis is an excessively produced and accumulated extracellular matrix (ECM). By synthesizing ECM, cardiac fibroblasts (CFs) serve a central role in inducing and developing cardiac fibrosis ([@b5-mmr-17-01-1775]). The transforming growth factor-β1 (TGF-β1) pathway induces organ fibrosis by mediating its downstream effectors, which are a family of proteins termed Smads. Activated Smads form complexes and mediate nuclear translocation, which leads to initiation of the transcription of genes encoding the ECM ([@b6-mmr-17-01-1775]). It has also been reported that the proliferation of the ECM, and ECM synthesis, were increased in human CFs incubated under high-glucose conditions ([@b7-mmr-17-01-1775]). However, the exact molecular mechanism has yet to be fully elucidated. Inhibition of CFs may be an effective strategy for the treatment of cardiac fibrosis of DbCM.

Matrine, the active molecule of *Sophora alopecuroides* L. (formula: C~15~H~24~N~2~O), has been gathering interest in the research community due to its potent and various biological activities. Results from a previous study published by the present authors indicated that matrine improved the left ventricular (LV) function of animals in an experimental DbCM model ([@b8-mmr-17-01-1775]). The anti-fibrotic activity of matrine on organ fibrosis via inhibition of the TGF-β/Smad pathway has also been suggested by another previously published study ([@b9-mmr-17-01-1775]). In the present study, the anti-fibrotic effect of matrine on cardiac fibrosis was investigated with an experimental DbCM model. In the *in vivo* part of the study, the effects of matrine on cardiac function and compliance were studied. In the *in vitro* part, the possible molecular mechanisms involved in the anti-fibrotic activity of matrine were investigated. The results of the present study should add further to our in-depth understanding of the pathological mechanism of cardiac fibrosis associated with DbCM. Furthermore, the results from this study should provide a theoretical foundation for the application of matrine-based compounds in DbCM treatment.

Materials and methods
=====================

### Animal experimental protocol

An experimental animal model of DbCM was induced as described previously in 7-week oldmale and female (1:1) Sprague-Dawley rats (weight, 180--220 g) provided by Animal Experimental Center of Xi\'an Jiaotong University ([@b10-mmr-17-01-1775]). The rats were raised in independent cages in a 12-h light/dark cycle, 25±2°C and 50% humidity. Animals had access to standard chow and clean water *ad libitum*. Intraperitoneal injection of streptozotocin (STZ; 65 mg/kg body weight) was employed to induce diabetes in rats. Prior to the induction of diabetes, rats were administered with matrine (Sigma-Aldrich; Merck KGaA, Darmstadt, Germany) orally at a dose of 300 mg/body weight per day for 10 days. Further details of the treatments, and the treatment groups, are provided in [Table I](#tI-mmr-17-01-1775){ref-type="table"}. In the present study, all animal experimental procedures were approved by the Experimental Animal Use Ethics Committee of Xi\'an Jiaotong University, and were performed in accordance with guidelines for the Care and Use of Laboratory Animals issued by the Chinese Council on Animal Research.

### Invasive hemodynamic evaluation of cardiac function

An invasive hemodynamic method described in our previous study ([@b11-mmr-17-01-1775]) was employed to evaluate the cardiac functions. Briefly, following anesthetization with chloral hydrate (10% v/v, 0.85 mg/kg body weight), a Mikro-Tip catheter transducer (Millar Instruments, Houston, TX, USA) was intubated into the left ventricle via the right carotid artery. Signals captured by the transducer were inputted into the PowerLab 4/25 Biological Information Analysis system (ADInstruments, Dunedin, New Zealand), from which the parameters, including LV end-diastolic pressure (LVEDP), LV systolic pressure (LVSP), positive maximal rate of LV increased pressure (+LVdP/dt~max~) and negative maximal rate of LV increased pressure (-LVdP/dt~max~), were outputted.

### Cardiac compliance assessments

By plotting a pressure-volume (P-V) curve from the measurements, cardiac compliance was evaluated in isolated perfused hearts. K-H buffering solution (95% O~2~/5% CO~2~ at 37°C) was used to perfuse the isolated Langendorff hearts. Through left atrial appendage and mitral valves, a non-compliant balloon filled with K-H solution was inserted into the left ventricle. The non-compliant balloon was connected to a pressure transducer (Millar Instruments), and the measurements were recorded using the PowerLab 4/25 Biological Information Analysis system (ADInstruments). LVDP was recorded when the volume of the balloon increased from 0.06 to 0.42 ml. Based on these measurements, the P-V curve was plotted.

### Cardiac collagen staining

Sirius red staining was used to visualize collagens in cardiac tissue. Following harvesting and trimming, cardiac tissues were fixed in neutral buffered formalin (10%, v/v) at room temperature for 10 h. Subsequently, the cardiac tissue was embedded in paraffin and sectioned into 4 µm-thick slices. A Picro Sirius Red stain kit (cat. no. ab150681; Abcam, Cambridge, UK) was used to treat the sections, according to the protocol provided by the manufacturer. Images were captured using a phase-contrast microscope. The addition of Sirius Red stain specifically enabled the positive staining of collagens.

### Isolation of primary CFs

Primary CFs were isolated from the left ventricles of neonatal SD rats following the protocol described in a previous study ([@b12-mmr-17-01-1775]). After having been harvested from 2-day-old SD rats, the hearts were minced and digested using type II collagenase (120 U/ml; Beijing Solarbio Science and Technology Co., Ltd., Beijing, China). The dissociated cells were collected by centrifugation (200 × g for 8 min at room temperature) and further cultured in MEM medium (Hyclone™) supplemented with fetal bovine serum (FBS; 10%, Hyclone™) (both from GE Healthcare Life Sciences, Shanghai, China) and penicillin-streptomycin antibiotic mix (Sigma-Aldrich; Merck KGaA). Cells were incubated in a humidified incubator under conditions of 95% fresh air and 5% CO~2~ at 37°C. The adherent cells were cultured to reach over 80% confluence. In excess of 95% of the collected cells were vimentin-positive/α-actin-negative. Cells from passages 2--3 were used. [Table II](#tII-mmr-17-01-1775){ref-type="table"} shows the details of grouping, and treatments of the isolated cells.

### MTT assay

MTT assay was used to assess the cell viability of isolated CFs. After seeding into a 96-well plate, cultured CFs were subsequently incubated at 37°C with matrine at serial concentrations of 0.25, 0.5, 1.0, 1.5, 2.0 and 2.5 mmol/l for 48 h. MTT (5 mg/ml) was then added into each well, and the cells were incubated for a further 4 h. Dimethyl sulfoxide (DMSO) was added to dissolve the resultant formazan crystals. Measurements of absorbance at 540 nm (A~540~) were recorded using a plate reader (Bio-Rad Laboratories, Inc., Hercules, CA, USA). Cell viability was defined according to the formula: (A~540~ of matrine -- treated cells/A~540~ of control cells) × 100%.

### Western blotting

The RIPA lysis buffer system (Santa Cruz Biotechnology, Inc., Dallas, TX, USA) with phenylmethylsulfonylfluoride (PMSF; Santa Cruz Biotechnology, Inc.) was used to obtain an homogenate of harvested cardiac tissue and cultured CFs, as per the manufacturer\'s instructions. Following centrifugation (12,500 × g) at 4°C for 10 min, the supernatants were collected. The total protein concentration was detected using a bicinchoninic acid (BCA) protein assay kit (Santa Cruz Biotechnology, Inc.). Proteins were subjected to 8% SDS-PAGE, and subsequently separated by vertical electrophoresis. The samples were then transferred to polyvinylidene fluoride (PVDF) membranes (EMD Millipore, Billerica, MA, USA) electrically at 10--12 V for 50 min. Specific primary antibodies against TGF-β1 (cat. no. SC7892, 1:1,000; Santa Cruz Biotechnology, Inc.), Smad2 (cat. no. ab40855, 1:2,000), Smad3 (cat. no. ab28379, 1:2,000) (both from Abcam), Smad7 (cat. no. PA1-41506, 1:2,000; Thermo Fisher Scientific, Inc., Waltham, MA, USA), phospho-Smad2 (cat. no. ab53100, 1:2,000), phospho-Smad3 (cat. no. ab52903, 1:2,000) (both from Abcam), collagen I (cat. no. 5D8-G9, 1:2,000; Thermo Fisher Scientific, Inc.) and GAPDH (cat. no. ab8245, 1:5,000; Abcam) were used to incubate the membranes at 4°C for 12 h. After washing, corresponding horseradish peroxidase (HRP)-conjugated secondary antibodies (cat. no. ab13168, 1:1,000; Abcam) (cat. nos. sc-2350 and sc-2371, 1:1,000; Santa Cruz Biotechnology, Inc.) were used to incubate the membranes at room temperature for 30 min. The membranes were developed using Western Blotting Luminal reagent (Santa Cruz Biotechnology, Inc.), and the bands were visualized on X-ray film in a dark room.

### Statistical analysis

Data in the present study are presented as the mean ± standard deviation. The differences between groups were analyzed using one-way analysis of variance, and statistical analysis was performed with SPSS software, version 17.0 (SPSS, Inc., Chicago, IL, USA). P\<0.05 was considered to indicate a statistically significant difference.

Results
=======

### Matrine attenuates left ventricular functions impairment in experimental rat model of DbCM

The experimental rat model of DbCM is characterized by elevated blood glucose levels and deteriorated LV function. Matrine treatment did not change the blood glucose levels in diabetic animals. The LV functions of control animals were not affected by matrine. However, matrine administration increased LVSP, +LVdP/dt~max~ and -LVdP/dt~max~, whereas LVEDP was decreased in the experimental rat model of DbCM. These results were demonstrated in [Table III](#tIII-mmr-17-01-1775){ref-type="table"}.

### Matrine recovers cardiac compliance loss in experimental rat model of DbCM

As demonstrated in the P-V curve in [Fig. 1](#f1-mmr-17-01-1775){ref-type="fig"}, the LV compliance was markedly impaired in isolated hearts from rats with DbCM. These changes were demonstrated by the significant P-V curve leftward shift. However, the P-V curve of isolated hearts from the DbCM+Mat group displayed a significant rightward shift, indicating markedly recovered LV compliance.

### Matrine inhibits cardiac fibrosis induced by the activation of the TGF-β1/Smad signaling pathway in rats with DbCM

Sirius red staining was used to evaluate the extent of cardiac fibrosis, and captured images are shown in [Fig. 2A](#f2-mmr-17-01-1775){ref-type="fig"}. Compared with the Ctrl and Mat groups, the optical density of Sirius Red staining increased markedly in the DbCM group, suggesting the occurrence of aggravated cardiac fibrosis. It was also observed that the optical density of Sirius Red staining decreased markedly in the DbCM+Mat group, indicating that matrine treatment alleviated cardiac fibrosis. [Fig. 2B](#f2-mmr-17-01-1775){ref-type="fig"} demonstrates the effects of matrine on the TGF-β1/Smad signaling pathway. Compared with Ctrl and Mat, the protein expression level of TGF-β1 increased in the DbCM group, but was markedly reduced by matrine administration in the DbCM group. Correspondingly, compared with Ctrl and Mat, the phosphorylation levels of Smad2 and 3 were also revealed to be elevated in DbCM, indicating activation of the TGF-β1/Smad signaling pathway. By contrast, matrine treatment markedly decreased the expression level of TGF-β1, and further inhibited phosphorylation of Smad2 and Smad3 in the DbCM+Mat group. As a result, the expression level of collagen I increased markedly in the DbCM group, but decreased in the DbCM+Mat group. The expression level of inhibitory Smad (I-Smad), namely Smad7, was shown to be decreased in the DbCM group, although this was not significantly affected by matrine treatment.

### Matrine at low concentrations exerts no inhibitory effects on cell proliferation of CFs incubated under high-glucose conditions

As shown in [Fig. 3](#f3-mmr-17-01-1775){ref-type="fig"}, the cell viability was assessed by MTT assay. The high-glucose-incubated CFs were treated with matrine at serial concentrations. Starting at 2.0 mmol/l, the viability of the CFs was significantly decreased. Therefore, matrine at concentrations of 0.25, 0.5 and 1.0 mmol/l were identified as the non-cytotoxic concentrations that were selected for subsequent experiments.

### Matrine treatment inhibits collagen synthesis by suppressing activation of the TGF-β1/Smad signaling pathway in high-glucose-incubated CFs

As shown in [Fig. 4](#f4-mmr-17-01-1775){ref-type="fig"}, the effects of matrine on the TGF-β1/Smad signaling pathway in cultured CFs were also investigated in the present study. The expression of TGF-β1, as well as Smad2 and 3 phosphorylation levels, were significantly increased in the CFs incubated under high glucose conditions. Matrine treatment decreased the levels of TGF-β1 and phosphorylated Smad2/3 in a concentration-dependent manner. As a result, also in a concentration-dependent manner, matrine decreased collagen I expression in high-glucose-incubated CFs. Exposure to a high concentration of glucose suppressed the expression of Smad7, although this was not affected by matrine.

Discussion
==========

Diabetic macro- and micro-vascular complications are the predominant causes of mortality due to diabetes. DbCM is one of the principal clinical manifestations of diabetic cardiovascular complications. DbCM is classified as a heart disease independent from other heart diseases, including congenital heart disease, coronary artery heart disease and valvular heart disease ([@b13-mmr-17-01-1775]). DbCM is characterized by cardiac remodeling, congestive heart failure and arrhythmias ([@b14-mmr-17-01-1775]).

Cardiac fibrosis is one of the essential pathological characteristics of cardiac remodeling, leading to cardiac structural and functional alterations ([@b15-mmr-17-01-1775]). It was considered that cardiac fibrosis was associated with cardiac dysfunction and cellular metabolic abnormalities attributable to diabetes ([@b16-mmr-17-01-1775],[@b17-mmr-17-01-1775]). Clearly evident cardiac fibrosis has been identified in diabetic hearts, according to previous studies ([@b18-mmr-17-01-1775]). CFs are activated in diabetic hearts, and exert a vital role in regulating cardiac extracellular matrix synthesis and deposition ([@b5-mmr-17-01-1775]), causing cardiac dysfunction and myocardium stiffening ([@b19-mmr-17-01-1775]). In the present study, it was revealed that the LV functions were significantly impaired in rats with DbCM. The chamber stiffness markedly increased in hearts isolated from rats with DbCM.

Many diabetic pathological products, including catecholamines, endothelin, insulin- like growth factor-1, advanced glycation end products and TGF-β1, have been correlated with organ fibrosis ([@b20-mmr-17-01-1775]--[@b22-mmr-17-01-1775]). The molecular mechanism of cardiac fibrosis in DbCM has yet to be fully elucidated. Previous studies indicated that the TGF-β1-induced signaling pathway exerts an important participatory role in cardiac fibrosis under certain cardiac pathological conditions ([@b23-mmr-17-01-1775],[@b24-mmr-17-01-1775]). As transcription factors, Smads are the downstream effectors of TGF-β1, which initiate transcription of genes encoding ECM components ([@b25-mmr-17-01-1775],[@b26-mmr-17-01-1775]). Studies have demonstrated that activation of the TGF-β1/Smad signaling pathway is responsible for hepatic, pulmonary and pancreatic fibrosis ([@b6-mmr-17-01-1775]).

Specifically, the R-Smads (generally Smad2 and 3) are activated following phosphorylation ([@b27-mmr-17-01-1775]). The I-Smad, also termed Smad7, suppresses the phosphorylation of Smad2/3 to inhibit the initiation of downstream target-gene transcription ([@b6-mmr-17-01-1775],[@b25-mmr-17-01-1775]). In the present study, in hearts harvested from rats with DbCM, the expression level of TGF-β1 and phosphorylation levels of Smad2/3 were increased markedly, indicating that the TGF-β1/Smad signaling pathway was activated. At the same time, expression of Smad7 was shown to be decreased in diabetic hearts, which also contributed to the activation of TGF-β1/Smad signaling. In CFs incubated under high glucose conditions, the TGF-β1/Smad signaling pathway was also shown to be activated, as revealed by increased TGF-β1 expression, decreased Smad7 expression and elevated levels of Smad2/3 phosphorylation. As a result, the synthesis of collagen I was shown to beincreased *in vivo* and *in vitro*.

Extracted from the Chinese medical herb Kushen (*Sophora alopecuroides L*.), matrine has been demonstrated to be one of the most important bioactive pharmacological components ([@b28-mmr-17-01-1775]--[@b30-mmr-17-01-1775]). Matrine was shown to affect the bioactivities of immune regulation, anti-inflammation and antioxidation ([@b8-mmr-17-01-1775],[@b31-mmr-17-01-1775]). Prompted by a study on the anti-fibrotic effect of matrine in several organs, including liver and kidneys ([@b29-mmr-17-01-1775]), the present authors chose to investigate the effects of matrine on cardiac fibrosis in the present study. It was shown that ECM synthesis and deposition were suppressed in a rat model of DbCM where cardiac fibrosis was clearly in evidence. Matrine administration attenuated cardiac chamber stiffness, and thus the LV systolic and diastolic functions were improved.

According to previous studies, TGF-β1/Smad signaling activation in CFs was shown to induce cardiac fibrosis. Several agents, including efonidipine and tanshinone, inhibited cardiac fibrosis by inhibiting this pathway ([@b32-mmr-17-01-1775],[@b33-mmr-17-01-1775]). In the present study, the potential molecular mechanism of matrine\'s anti-fibrosis effect in DbCM was investigated. The *in vivo* data revealed that matrine administration inhibited activation of the TGF-β1/Smad signaling pathway by suppressing the expression of TGF-β1 and phosphorylation of Smad2/3 in diabetic hearts. As a result, the accumulation of collagen I in myocytes was attenuated. However, the expression of the I-Smad, Smad7, was not shown to be affected by matrine. In the *in vitro* part of the present study, matrine at low concentrations (i.e., in order to avoid its cytotoxicity) was used to treat the high-glucose-incubated CFs. The results suggested that matrine at non-toxic concentrations deactivated the TGF-β1/Smad signaling pathway by suppressing the expression of TGF-β1 and phosphorylation of Smad2/3 in a concentration-dependent manner, rather than affecting the expression of Smad7. Hence, the synthesis of collagen I in CFs was correspondingly reduced.

In conclusion, the present study has shown that a loss of cardiac compliance and function are the features of DbCM characterized by cardiac fibrosis. Secondly, the TGF-β1/Smad signaling pathway was activated to induce fibrosis in diabetic hearts and CFs incubated under high glucose conditions. Thirdly, matrine was shown to exert anti-fibrosis effects to improve cardiac compliance and function by suppressing activation of the TGF-β1/Smad signaling pathway in CFs in DbCM.
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![Cardiac compliance detection and plotting in isolated hearts. The line chart in this figure demonstrates the P-V (left ventricular diastolic pressure-left ventricular volume) curve of isolated hearts from the Ctrl, Mat, DbCM and DbCM+Mat groups. Results are presented as the mean ± standard deviation. Approximately linear trends are shown. \*P\<0.05 vs. Ctrl; \*\*P\<0.05 vs. Mat; \*\*\*P\<0.05 vs. DbCM. Ctrl, control; Mat, matrine; DbCM, diabetic cardiomyopathy.](MMR-17-01-1775-g00){#f1-mmr-17-01-1775}

![Collagen deposition and TGF-β1/Smad signaling pathway activation in cardiac tissue. (A) In the left part of the figure, captured images of Sirius Red staining of cardiac tissue harvested from each group (Ctrl, Mat, DbCM and DbCM+Mat) are shown. The bar chart on the right shows the values of the optical densities of Sirius Red in each group (results are presented as the mean ± standard deviation). (B) Immunoblots of TGF-β1, Smad2, phospho (p)-Smad2, Smad3, p-Smad3, Smad7, collagen I and the loading control, GAPDH, are shown. The bar chart on the right shows the relative expression levels of TGF-β1 (TGF-β1/GAPDH), Smad7 (Smad7/GAPDH), phosphorylated Smad2 (phospho-Smad2/Smad2), phosphorylated Smad3 (phospho-Smad3/Smad3) and collagen I (collagen I/GAPDH). \*P\<0.05 vs. Ctrl; \*\*P\<0.05 vs. Mat; \*\*\*P\<0.05 vs. DbCM. TGF-β1, transforming growth factor-β1. Ctrl, control; Mat, matrine; DbCM, diabetic cardiomyopathy.](MMR-17-01-1775-g01){#f2-mmr-17-01-1775}

![Cell viability of isolated CFs incubated with matrine at different concentrations. This figure demonstrates the results of the MTT assay, which determined the cell viability rate (%) of isolated CFs incubated with matrine at concentrations of 0.0, 0.5, 1.0, 1.5, 2.0 and 2.5 mmol/l. \*P\<0.05 vs. the previous concentration in the series. CF, cardiac fibroblast.](MMR-17-01-1775-g02){#f3-mmr-17-01-1775}

![TGF-β1/Smad signaling pathway activation in isolated cardiac fibroblasts. (A) Immunoblots of TGF-β1, Smad2, phospho (p)-Smad2, Smad3, p-Smad3, Smad7 and GAPDH in isolated cardiac fibroblasts treated with serial concentrations of matrine (0.0, 0.5, 1.0, 1.5, 2.0 and 2.5 mmol/l) and/or HG medium are shown. (B) The bar chart shows the relative expression levels of TGF-β1 (TGF-β1/GAPDH). (C) Bar charts also show the phosphorylation of Smad2 (p-Smad2/Smad2), (D) the phosphorylation of Smad3 (p-Smad3/Smad3), (E) the relative expression level of Smad7 (Smad7/GAPDH), and (F) the relative expression level of collagen I (collagen I/GAPDH). Data shown in B-F represent the mean ± standard deviation. \*P\<0.05 vs. first column; \*\*P\<0.05 vs. third column; \*\*\*P\<0.05 vs. fourth column; ^\#^P\<0.05 vs. fifth column. TGF-β1, transforming growth factor-β1.](MMR-17-01-1775-g03){#f4-mmr-17-01-1775}

###### 

Treatment of the rats in the different groups.

             Treatment 1            Treatment 2                                                                                                                                     
  ---------- ---------------------- ---------------------------------------------------------------------------------------- ------------------------------------------------------ -----------------------------------------------------------------
  Ctrl       Physiological saline   10 days prior to injection; oral administration; equal volume to matrine                 Sodium citrate buffer (pH 4.5)                         Equal volume to STZ injection; single intraperitoneal injection
  DbCM       Physiological saline   10 days before injection; oral administration; equal volume to matrine                   STZ (dissolved in sodium citrate buffer, pH 4.5)       65 mg/kg body weight; single intraperitoneal injection
  Mat        Matrine                10 days before injection; oral administration; 200 mg/kg/day for 10 consecutive days     Sodium citrate buffer, pH 4.5                          Equal volume to STZ injection; single intraperitoneal injection
  DbCM+Mat   Matrine                10 days prior to injection; oral administration; 200 mg/kg/day for 10 consecutive days   STZ (dissolved in sodium citrate buffer with pH 4.5)   65 mg/kg body weight; single intraperitoneal injection

Ctrl, control; Mat, matrine; STZ, streptozotocin; DbCM, diabetic cardiomyopathy.

###### 

Treatment of CFs in different groups.

           Treatment 1                                                  Treatment 2                                   
  -------- ------------------------------------------------------------ --------------------- ----------------------- -------------------------------------
  Ctrl     Vehicle solution                                             Incubation for 48 h   Normal glucose medium   Glucose concentration at 5.5 mmol/l
  HG       Vehicle solution                                             Incubation for 48 h   HG medium               Glucose concentration at 25 mmol/l
  Mat      Matrine solution (0.25, 0.5, 1.0, 1.5, 2.0 and 2.5 mmol/l)   Incubation for 48 h   Normal glucose medium   Glucose concentration at 5.5 mmol/l
  HG+Mat   Matrine solution (0.25, 0.5, 1.0, 1.5, 2.0 and 2.5 mmol/l)   Incubation for 48 h   HG medium               Glucose concentration at 25 mmol/l

CFs, cardiac fibroblasts; Ctrl, control; HG, high glucose; Mat, matrine.

###### 

Hemodynamic parameters and blood glucose concentration comparisons between groups (n=3).

  Group      Blood glucose concentration (mmol/l)                                                                        Left ventricular systolic pressure (mmHg)                                                                    Left ventricular end-diastolic pressure (mmHg)                                                               +Left ventricular dP/dt~max~ (mmHg/sec)                                                                           -Left ventricular dP/dt~max~ (mmHg/sec)
  ---------- ----------------------------------------------------------------------------------------------------------- ------------------------------------------------------------------------------------------------------------ ------------------------------------------------------------------------------------------------------------ ----------------------------------------------------------------------------------------------------------------- -----------------------------------------------------------------------------------------------------------------
  Ctrl       9.25±3.32                                                                                                   107.82±12.61                                                                                                 22.18±5.59                                                                                                   1,988.35±221.54                                                                                                   2,677.16±345.27
  Mat        10.15±3.10                                                                                                  112.37±13.05                                                                                                 23.29±5.75                                                                                                   1,973.00±224.45                                                                                                   2,713.05±332.19
  DbCM       18.27±5.56^[a](#tfn3-mmr-17-01-1775){ref-type="table-fn"},[b](#tfn4-mmr-17-01-1775){ref-type="table-fn"}^   68.54±9.75^[a](#tfn3-mmr-17-01-1775){ref-type="table-fn"},[b](#tfn4-mmr-17-01-1775){ref-type="table-fn"}^    64.78±6.14^[a](#tfn3-mmr-17-01-1775){ref-type="table-fn"},[b](#tfn4-mmr-17-01-1775){ref-type="table-fn"}^    549.43±95.18^[a](#tfn3-mmr-17-01-1775){ref-type="table-fn"},[b](#tfn4-mmr-17-01-1775){ref-type="table-fn"}^       1,389.75±154.11^[a](#tfn3-mmr-17-01-1775){ref-type="table-fn"},[b](#tfn4-mmr-17-01-1775){ref-type="table-fn"}^
  DbCM+Mat   19.34±4.91^[a](#tfn3-mmr-17-01-1775){ref-type="table-fn"},[b](#tfn4-mmr-17-01-1775){ref-type="table-fn"}^   82.10±7.45^[a](#tfn3-mmr-17-01-1775){ref-type="table-fn"}--[c](#tfn5-mmr-17-01-1775){ref-type="table-fn"}^   48.20±5.61^[a](#tfn3-mmr-17-01-1775){ref-type="table-fn"}--[c](#tfn5-mmr-17-01-1775){ref-type="table-fn"}^   1,244.75±111.43^[a](#tfn3-mmr-17-01-1775){ref-type="table-fn"}--[c](#tfn5-mmr-17-01-1775){ref-type="table-fn"}^   1,799.48±177.42^[a](#tfn3-mmr-17-01-1775){ref-type="table-fn"}--[c](#tfn5-mmr-17-01-1775){ref-type="table-fn"}^

P\<0.05 vs. Ctrl

P\<0.05 vs. Mat

P\<0.05 vs. DbCM. Ctrl, control; Mat, matrine; DbCM, diabetic cardiomyopathy.
